EP3823617A4 - Enantiomerically purified gper agonist for use in treating disease states and conditions - Google Patents
Enantiomerically purified gper agonist for use in treating disease states and conditions Download PDFInfo
- Publication number
- EP3823617A4 EP3823617A4 EP19842049.9A EP19842049A EP3823617A4 EP 3823617 A4 EP3823617 A4 EP 3823617A4 EP 19842049 A EP19842049 A EP 19842049A EP 3823617 A4 EP3823617 A4 EP 3823617A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- conditions
- disease states
- treating disease
- enantiomerically purified
- gper agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101150007919 Gper1 gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP24161261.3A EP4356913A2 (en) | 2018-07-21 | 2019-07-22 | Enantiomerically purified gper agonist for use in treating disease states and conditions |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701726P | 2018-07-21 | 2018-07-21 | |
| PCT/US2019/042827 WO2020023391A1 (en) | 2018-07-21 | 2019-07-22 | Enantiomerically purified gper agonist for use in treating disease states and conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24161261.3A Division EP4356913A2 (en) | 2018-07-21 | 2019-07-22 | Enantiomerically purified gper agonist for use in treating disease states and conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP3823617A1 EP3823617A1 (en) | 2021-05-26 |
| EP3823617A4 true EP3823617A4 (en) | 2022-04-20 |
| EP3823617B1 EP3823617B1 (en) | 2024-03-06 |
Family
ID=69160978
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24161261.3A Pending EP4356913A2 (en) | 2018-07-21 | 2019-07-22 | Enantiomerically purified gper agonist for use in treating disease states and conditions |
| EP19842049.9A Active EP3823617B1 (en) | 2018-07-21 | 2019-07-22 | Enantiomerically purified gper agonist for use in treating disease states and conditions |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24161261.3A Pending EP4356913A2 (en) | 2018-07-21 | 2019-07-22 | Enantiomerically purified gper agonist for use in treating disease states and conditions |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US20200024262A1 (en) |
| EP (2) | EP4356913A2 (en) |
| JP (1) | JP2021532148A (en) |
| KR (1) | KR20210049778A (en) |
| CN (1) | CN112469409A (en) |
| AU (1) | AU2019310029A1 (en) |
| BR (1) | BR112021001031A2 (en) |
| CA (1) | CA3107109A1 (en) |
| IL (1) | IL280283A (en) |
| MX (1) | MX2021000809A (en) |
| WO (1) | WO2020023391A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022216893A1 (en) * | 2021-04-08 | 2022-10-13 | Linnaeus Therapeutics, Inc. | Oncologic variations associated with cancer and methods of treatment |
| AU2022275860A1 (en) * | 2021-05-19 | 2023-12-07 | Linnaeus Therapeutics, Inc. | Diagnostic methods and compositions for treatment of cancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007019180A2 (en) * | 2005-08-04 | 2007-02-15 | Science & Technology Corporation @ Unm | Compounds for binding to eralpha/beta and gpr30, methods of treating disease states and conditions mediated through these receptors and identification thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US251870A (en) * | 1882-01-03 | Automatic gate | ||
| WO2008153945A2 (en) * | 2007-06-06 | 2008-12-18 | University Of South Florida | Nutraceutical co-crystal compositions |
| US8975249B2 (en) * | 2010-11-01 | 2015-03-10 | Celgene Avilomics Research, Inc. | Heterocyclic compounds and uses thereof |
| US10251870B2 (en) * | 2015-03-06 | 2019-04-09 | Stc.Unm | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity |
| US11236074B2 (en) * | 2015-04-06 | 2022-02-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for decreasing, or preventing or reversing gain of, skin pigmentation in a mammalian subject |
| DK3471722T3 (en) | 2016-06-17 | 2023-12-04 | Univ Pennsylvania | Compounds, compositions and methods for preventing and/or treating cancer |
-
2019
- 2019-07-22 CN CN201980048925.4A patent/CN112469409A/en active Pending
- 2019-07-22 EP EP24161261.3A patent/EP4356913A2/en active Pending
- 2019-07-22 US US16/518,516 patent/US20200024262A1/en not_active Abandoned
- 2019-07-22 WO PCT/US2019/042827 patent/WO2020023391A1/en unknown
- 2019-07-22 MX MX2021000809A patent/MX2021000809A/en unknown
- 2019-07-22 KR KR1020217002117A patent/KR20210049778A/en unknown
- 2019-07-22 BR BR112021001031-9A patent/BR112021001031A2/en unknown
- 2019-07-22 JP JP2021504360A patent/JP2021532148A/en active Pending
- 2019-07-22 EP EP19842049.9A patent/EP3823617B1/en active Active
- 2019-07-22 AU AU2019310029A patent/AU2019310029A1/en active Pending
- 2019-07-22 CA CA3107109A patent/CA3107109A1/en active Pending
- 2019-11-13 US US16/682,821 patent/US10934277B2/en active Active
-
2021
- 2021-01-19 IL IL280283A patent/IL280283A/en unknown
- 2021-02-25 US US17/184,870 patent/US11760749B2/en active Active
- 2021-05-24 US US17/328,590 patent/US20220089576A1/en active Pending
-
2023
- 2023-08-03 US US18/364,690 patent/US20230382896A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007019180A2 (en) * | 2005-08-04 | 2007-02-15 | Science & Technology Corporation @ Unm | Compounds for binding to eralpha/beta and gpr30, methods of treating disease states and conditions mediated through these receptors and identification thereof |
Non-Patent Citations (1)
| Title |
|---|
| BURAI ET AL.: "Highly efficient synthesis and characterization of the GPR30-selective agonist G-1 and related tetrahydroquinoline analogs", ORG. BIOMOL. CHEM., vol. 8, no. 9, 16 March 2010 (2010-03-16), pages 2252 - 2259, XP055899304, ISSN: 1477-0520, DOI: 10.1039/c001307b * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021532148A (en) | 2021-11-25 |
| EP3823617A1 (en) | 2021-05-26 |
| EP4356913A2 (en) | 2024-04-24 |
| MX2021000809A (en) | 2021-06-15 |
| WO2020023391A1 (en) | 2020-01-30 |
| BR112021001031A2 (en) | 2021-04-13 |
| US20200024262A1 (en) | 2020-01-23 |
| CA3107109A1 (en) | 2020-01-30 |
| AU2019310029A1 (en) | 2021-02-04 |
| US20220033385A1 (en) | 2022-02-03 |
| KR20210049778A (en) | 2021-05-06 |
| IL280283A (en) | 2021-03-01 |
| US20200140417A1 (en) | 2020-05-07 |
| US11760749B2 (en) | 2023-09-19 |
| EP3823617B1 (en) | 2024-03-06 |
| US10934277B2 (en) | 2021-03-02 |
| US20220089576A1 (en) | 2022-03-24 |
| US20230382896A1 (en) | 2023-11-30 |
| CN112469409A (en) | 2021-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3695415A4 (en) | Systems and methods for ensuring data security in the treatment of diseases and disorders using digital therapeutics | |
| EP3746135A4 (en) | Methods and compounds for treating disorders | |
| EP3931189A4 (en) | Azepino-indoles and other heterocycles for treating brain disorders | |
| EP3634442A4 (en) | Methods for treating and preventing diseases | |
| EP3817733A4 (en) | Composition and method for treating pain | |
| EP3247359A4 (en) | Composition and method for treating seizure disorders | |
| EP3858977A4 (en) | Strain for preventing and treating metabolic diseases and use thereof | |
| EP3641754A4 (en) | Sleep disorder compositions and treatments thereof | |
| EP3513796A4 (en) | Sleep disorder improvement agent and method for improving sleep disorders | |
| EP3589283A4 (en) | Method and composition for treating eating disorders | |
| EP3858353A4 (en) | Pharmaceutical composition for preventing and treating nitm and pharmaceutical use thereof | |
| EP3678640A4 (en) | Methods and compositions for treating inflammatory skin disease with recombinant microorganisms | |
| ZA202106620B (en) | Subscription to changes in policy data | |
| EP3866736A4 (en) | Methods and devices for treating sleep apnea | |
| EP3677265A4 (en) | Composition for preventing or treating sleep disorders | |
| EP3556382A4 (en) | Method for preventing and treating skin fibrosis | |
| IL280283A (en) | Enantiomerically purified gper agonist for use in treating disease states and conditions | |
| EP3870154A4 (en) | Compositions and methods for preventing and treating antibiotic induced pathologies using probiotics in the biofilm state | |
| EP3762505A4 (en) | Compositions and methods for treating parkinson's disease | |
| EP3831821A4 (en) | Compound for treating nervous system diseases and use thereof | |
| EP3737370A4 (en) | Compositions and methods for treating pain with wogonin | |
| EP3775217A4 (en) | Microrna-based compositions and methods used in disease treatment | |
| EP3554496A4 (en) | Methods and compositions for treating parkinson's disease | |
| IL275935A (en) | Thiophene derivative and use thereof | |
| EP3866861A4 (en) | Methods for treating and monitoring progranulin-associated disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20210119 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602019047958 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0031435000 Ipc: C07D0405040000 Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031435000 Ipc: C07D0405040000 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20220321 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/47 20060101ALI20220315BHEP Ipc: A61P 35/00 20060101ALI20220315BHEP Ipc: C07C 309/35 20060101ALI20220315BHEP Ipc: C07C 309/29 20060101ALI20220315BHEP Ipc: C07C 309/19 20060101ALI20220315BHEP Ipc: C07D 405/04 20060101AFI20220315BHEP |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20230929 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602019047958 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20240304 |